Quantum Genesis AI Corp.
Quantum Genesis AI Corp. is a U.S.-based development-stage biotechnology and industrial chemistry company focused on engineered enzymes for biotransformation and sustainable chemical manufacturing. Its work centers on applying quantum mechanics, molecular modeling, and enzyme engineering to improve chemical processes for pharmaceutical and other specialty-chemicals applications.
Fiscal year 2025 · change from previous year
Development 2016–2025
Business
Share of revenueCustom-designed enzymes intended to improve selectivity, activity, and specificity in chemical processes.
Enzyme-based process tools for active pharmaceutical ingredient manufacturing.
Research programs aimed at extending enzyme platforms into green chemistry use cases.
Customers
The company’s target customers are pharmaceutical manufacturers and other chemical producers that need more selective, step-efficient synthesis routes. It also aims to serve specialty-chemicals users in fragrances, flavors, sustainable materials, plastic degradation, and carbon capture applications. In practice, customers would buy the company’s enzyme technology to reduce process complexity, improve specificity, and support cleaner manufacturing.
Buy engineered enzymes to support active pharmaceutical ingredient production and improve process selectivity.
Use enzyme platforms for cleaner, more efficient manufacturing in fragrances, flavors, and related chemistries.
Explore enzyme applications in plastic degradation, carbon capture, and sustainable materials.
May fund development, provide scale-up support, or commercialize the technology through alliances.
Strategy
The company’s strategy is to advance engineered-enzyme technology from research into commercial use, starting with pharmaceutical API applications and then extending into adjacent specialty-chemicals markets. It also seeks strategic partnerships and outside financing to support development, scale-up, and broader commercialization. Building a scientific advisory capability and securing manufacturing/testing access are important to turning the platform into a repeatable business.
Initial market focus provides a clear industrial use case and validation path for the technology.
Fragrances, flavors, and sustainable chemistry broaden the addressable market beyond pharma.
Partnerships and scientific oversight can improve credibility, access, and commercialization speed.
Geography
The company is headquartered in San Diego, California, and its disclosed operations are U.S.-based. Its business model is not tied to a broad manufacturing footprint; instead, it relies on research, third-party testing facilities, and contract manufacturers for scale-up and enzyme production. Geography matters mainly through access to scientific talent, testing infrastructure, and outsourced manufacturing capacity.
Risks
The business is highly dependent on external funding, because it is still in development and has not generated revenue. Execution risk is elevated because enzyme scale-up depends on third-party manufacturers and testing facilities, while regulatory and intellectual-property dynamics can materially affect adoption in pharmaceutical and chemical markets.
- Funding shortfallImpact: CriticalLikelihood: High
The company has no firm financing arrangements and needs capital to continue development.
Exposure: Operations and commercialization
- Key-person dependenceImpact: HighLikelihood: High
The company is early-stage and has a very small workforce, increasing reliance on a few individuals.
Exposure: Scientific and operational continuity
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
Large-scale enzyme production is outsourced, creating supply, timing, and quality exposure.
Exposure: Product availability and scale-up
- Testing facility access constraintsImpact: MediumLikelihood: Low
The company relies on off-site testing facilities without formal agreements.
Exposure: R&D timelines and costs
- Regulatory and legal changesImpact: MediumLikelihood: Low
Biotransformation and chemical applications are exposed to evolving industry regulation.
Exposure: Market access and compliance
Accounting
Judgemental itemsThe company has recurring losses and negative operating cash flow, so continuation depends on future financing.
Impact: Affects financial statement presentation and investor assessment of survival risk
Financing has been raised through stock issuance, which changes equity structure and per-share economics.
Impact: Affects shareholders' equity and dilution analysis
Early-stage companies often use equity awards or founder-related issuances that require fair value measurement.
Impact: Can materially affect operating expenses
Additional debt increases financing costs and can affect net loss trends.
Impact: Affects other expense and cash flow
Similar listed companies
Publicly listed companies with a comparable business focus.
Quantum-Si Inc
QSI · Measuring & Controlling Devices, NEC
Kinetic Seas Inc.
KSEZ · Blank Checks
Genesis Energy, L.P
GEL · Pipe Lines (No Natural Gas)
Evogene Ltd.
EVGN · Agricultural Chemicals
Quantum Computing Inc.
QUBT · Services-Prepackaged Software
Qnity Electronics, Inc.
Q · Semiconductors & Related Devices
Last updated: 24/09/2026